Xenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals (XENE) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know [Yahoo! Finance]
Xenon Pharmaceuticals (XENE) had its price target lowered by Wedbush from $64.00 to $63.00. They now have an "outperform" rating on the stock.